Byterna therapeutics dedicates to explore the full potentials of circular mRNA and targeted in vivo delivery technologies in cell and gene therapy. Our leading pipeline focuses on cmRNA-based in vivo CAR-T therapy for blood cancers and autoimmune diseases.